For example, the potential role of cagrilintide in improving insulin sensitivity, reducing cardiovascular risk markers and regulating energy expenditure may offer therapeutic benefits in brain disorders exacerbated by metabolic impairments, such as Alzheimer’s disease [47,175,176,177,178,179]. Here, INS is linked to early-onset autosomal dominant Alzheimer disease.